APO RESEARCH · REPORT
Botanical Drug
Sales outsourcing is simply this: outsourcing a portion or entire sales activities to a trusted 3rd party sales team. Using a sales outsourcing partner allows companies to attract and maintain a sales force without having to make them full or part-time employees.
Product & engineering
Understand the product.
Sales outsourcing is simply this: outsourcing a portion or entire sales activities to a trusted 3rd party sales team. Using a sales outsourcing partner allows companies to attract and maintain a sales force without having to make them full or part-time employees.
Selected research
Industry Research
Botanical Drug Industry Research Report 2026
Market perspective
Sales outsourcing is simply this: outsourcing a portion or entire sales activities to a trusted 3rd party sales team. Using a sales outsourcing partner allows companies to attract and maintain a sales force without having to make them full or part-time employees.
Buchang Pharmaceuticals, China TCM, Tsumura, Schwabe, Tong Ren Tang, Jumpcan Pharmaceutical, Guangzhou Baiyunshan Pharmaceutical, etc. are the leaders of the industry.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 75% in 2019. Following Asia-Pacific, Europe is the second largest consumption place with the consumption market share of about 16%.
Read the full market overview
The classification of Botanical Drug includes Prescription Drug and OTC, and the proportion of OTC in 2019 was about 61%.
Botanical Drug is widely used for Cardiovascular, Tumor, Respiratory System, Others. The most proportion of Botanical Drug is Cardiovascular, and the proportion in 2019 was 30%.
Report Scope
This report quantifies the global Botanical Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Botanical Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Botanical Drug Market by Company
Buchang Pharmaceuticals
China TCM
Tsumura
Schwabe
Tong Ren Tang
Jumpcan Pharmaceutical
Guangzhou Baiyunshan Pharmaceutical
Yunnan Baiyao
Tasly Holding Group
Bionorica Se
Huarun 999
Taiji
Weleda
Kwangdong
GW Pharmaceuticals
Botanical Drug Segment by Type
Prescription Drug
OTC
Botanical Drug Segment by Application
Cardiovascular
Tumor
Respiratory System
Others
Botanical Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Botanical Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Botanical Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Botanical Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Botanical Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Drug
- OTC
Applications
- Cardiovascular
- Tumor
- Respiratory System
- Others
Companies covered
- Buchang Pharmaceuticals
- China TCM
- Tsumura
- Schwabe
- Tong Ren Tang
- Jumpcan Pharmaceutical
- Guangzhou Baiyunshan Pharmaceutical
- Yunnan Baiyao
- Tasly Holding Group
- Bionorica Se
- Huarun 999
- Taiji
- Weleda
- Kwangdong
- GW Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Botanical Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Prescription Drug
- 2.2.3 OTC
- 2.3 Botanical Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cardiovascular
- 2.3.3 Tumor
- 2.3.4 Respiratory System
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Botanical Drug Breakdown Data by Type
- 3.1 Global Botanical Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Botanical Drug Forecasted Market Size by Type (2027-2032)
4 Botanical Drug Breakdown Data by Application
- 4.1 Global Botanical Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Botanical Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Botanical Drug Market Perspective (2021-2032)
- 5.2 Global Botanical Drug Growth Trends by Region
- 5.2.1 Global Botanical Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Botanical Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Botanical Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Botanical Drug Market Dynamics
- 5.3.1 Botanical Drug Industry Trends
- 5.3.2 Botanical Drug Market Drivers
- 5.3.3 Botanical Drug Market Challenges
- 5.3.4 Botanical Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Botanical Drug Players by Revenue
- 6.1.1 Global Top Botanical Drug Players by Revenue (2021-2026)
- 6.1.2 Global Botanical Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Botanical Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Botanical Drug Head Office and Area Served
- 6.4 Global Botanical Drug Players, Product Type & Application
- 6.5 Global Botanical Drug Manufacturers Established Date
- 6.6 Global Botanical Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Botanical Drug Market Size (2021-2032)
- 7.2 North America Botanical Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Botanical Drug Market Size by Country (2021-2026)
- 7.4 North America Botanical Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Botanical Drug Market Size (2021-2032)
- 8.2 Europe Botanical Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Botanical Drug Market Size by Country (2021-2026)
- 8.4 Europe Botanical Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Botanical Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Botanical Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Botanical Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Botanical Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Botanical Drug Market Size (2021-2032)
- 10.2 South America Botanical Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Botanical Drug Market Size by Country (2021-2026)
- 10.4 South America Botanical Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Botanical Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Botanical Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Botanical Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Botanical Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Buchang Pharmaceuticals
- 12.1.1 Buchang Pharmaceuticals Company Information
- 12.1.2 Buchang Pharmaceuticals Business Overview
- 12.1.3 Buchang Pharmaceuticals Revenue in Botanical Drug Business (2021-2026)
- 12.1.4 Buchang Pharmaceuticals Botanical Drug Product Portfolio
- 12.1.5 Buchang Pharmaceuticals Recent Developments
- 12.2 China TCM
- 12.2.1 China TCM Company Information
- 12.2.2 China TCM Business Overview
- 12.2.3 China TCM Revenue in Botanical Drug Business (2021-2026)
- 12.2.4 China TCM Botanical Drug Product Portfolio
- 12.2.5 China TCM Recent Developments
- 12.3 Tsumura
- 12.3.1 Tsumura Company Information
- 12.3.2 Tsumura Business Overview
- 12.3.3 Tsumura Revenue in Botanical Drug Business (2021-2026)
- 12.3.4 Tsumura Botanical Drug Product Portfolio
- 12.3.5 Tsumura Recent Developments
- 12.4 Schwabe
- 12.4.1 Schwabe Company Information
- 12.4.2 Schwabe Business Overview
- 12.4.3 Schwabe Revenue in Botanical Drug Business (2021-2026)
- 12.4.4 Schwabe Botanical Drug Product Portfolio
- 12.4.5 Schwabe Recent Developments
- 12.5 Tong Ren Tang
- 12.5.1 Tong Ren Tang Company Information
- 12.5.2 Tong Ren Tang Business Overview
- 12.5.3 Tong Ren Tang Revenue in Botanical Drug Business (2021-2026)
- 12.5.4 Tong Ren Tang Botanical Drug Product Portfolio
- 12.5.5 Tong Ren Tang Recent Developments
- 12.6 Jumpcan Pharmaceutical
- 12.6.1 Jumpcan Pharmaceutical Company Information
- 12.6.2 Jumpcan Pharmaceutical Business Overview
- 12.6.3 Jumpcan Pharmaceutical Revenue in Botanical Drug Business (2021-2026)
- 12.6.4 Jumpcan Pharmaceutical Botanical Drug Product Portfolio
- 12.6.5 Jumpcan Pharmaceutical Recent Developments
- 12.7 Guangzhou Baiyunshan Pharmaceutical
- 12.7.1 Guangzhou Baiyunshan Pharmaceutical Company Information
- 12.7.2 Guangzhou Baiyunshan Pharmaceutical Business Overview
- 12.7.3 Guangzhou Baiyunshan Pharmaceutical Revenue in Botanical Drug Business (2021-2026)
- 12.7.4 Guangzhou Baiyunshan Pharmaceutical Botanical Drug Product Portfolio
- 12.7.5 Guangzhou Baiyunshan Pharmaceutical Recent Developments
- 12.8 Yunnan Baiyao
- 12.8.1 Yunnan Baiyao Company Information
- 12.8.2 Yunnan Baiyao Business Overview
- 12.8.3 Yunnan Baiyao Revenue in Botanical Drug Business (2021-2026)
- 12.8.4 Yunnan Baiyao Botanical Drug Product Portfolio
- 12.8.5 Yunnan Baiyao Recent Developments
- 12.9 Tasly Holding Group
- 12.9.1 Tasly Holding Group Company Information
- 12.9.2 Tasly Holding Group Business Overview
- 12.9.3 Tasly Holding Group Revenue in Botanical Drug Business (2021-2026)
- 12.9.4 Tasly Holding Group Botanical Drug Product Portfolio
- 12.9.5 Tasly Holding Group Recent Developments
- 12.10 Bionorica Se
- 12.10.1 Bionorica Se Company Information
- 12.10.2 Bionorica Se Business Overview
- 12.10.3 Bionorica Se Revenue in Botanical Drug Business (2021-2026)
- 12.10.4 Bionorica Se Botanical Drug Product Portfolio
- 12.10.5 Bionorica Se Recent Developments
- 12.11 Huarun 999
- 12.11.1 Huarun 999 Company Information
- 12.11.2 Huarun 999 Business Overview
- 12.11.3 Huarun 999 Revenue in Botanical Drug Business (2021-2026)
- 12.11.4 Huarun 999 Botanical Drug Product Portfolio
- 12.11.5 Huarun 999 Recent Developments
- 12.12 Taiji
- 12.12.1 Taiji Company Information
- 12.12.2 Taiji Business Overview
- 12.12.3 Taiji Revenue in Botanical Drug Business (2021-2026)
- 12.12.4 Taiji Botanical Drug Product Portfolio
- 12.12.5 Taiji Recent Developments
- 12.13 Weleda
- 12.13.1 Weleda Company Information
- 12.13.2 Weleda Business Overview
- 12.13.3 Weleda Revenue in Botanical Drug Business (2021-2026)
- 12.13.4 Weleda Botanical Drug Product Portfolio
- 12.13.5 Weleda Recent Developments
- 12.14 Kwangdong
- 12.14.1 Kwangdong Company Information
- 12.14.2 Kwangdong Business Overview
- 12.14.3 Kwangdong Revenue in Botanical Drug Business (2021-2026)
- 12.14.4 Kwangdong Botanical Drug Product Portfolio
- 12.14.5 Kwangdong Recent Developments
- 12.15 GW Pharmaceuticals
- 12.15.1 GW Pharmaceuticals Company Information
- 12.15.2 GW Pharmaceuticals Business Overview
- 12.15.3 GW Pharmaceuticals Revenue in Botanical Drug Business (2021-2026)
- 12.15.4 GW Pharmaceuticals Botanical Drug Product Portfolio
- 12.15.5 GW Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst